|
Indian Pediatr 2010;47: 305-306 |
|
Single-dose Azithromycin for Childhood Cholera
|
Wasif Ali Khan
Scientist, Clinical Sciences Division, ICDDR B, 68
Shaheed Tajuddin Ahmed Sharani, Mohakhali, Dhaka-1212, Bangladesh.
[email protected]
|
In this issue, Kaushik, et al.(1),
reconfirmed the statement made in an earlier study "single-dose
azithromycin has been established as an effective drug for the treatment
of cholera caused by susceptible strains of V cholera in both
adults and children" the same regimens were compared in adults with severe
cholera(2).
Though the study design was almost consistently
followed with the recent publication in Lancet and NEJM but the authors
used different outcome variable (72 h instead of 48 h), that made it
difficult to compare it with earlier studies(2-5). Although, in the
discussion, authors did state the discrepancies in using different
criteria for the clinical and bacteriological success rates, among the
references quoted, the success rate was based on 48 h definition in 4 out
of 5 relevant trial articles. Therefore, for a better comparison, I
reexamined the dataset of our study of azithromycin in childhood
cholera(4) and noted the rate of clinical and bacteriological success as
81% and 84%, respectively at 72 h. Thus, it is important that an
investigator conducting same type of clinical trial in different
population should try to use similar outcome variables as in earlier
published work.
The objective of evaluating single dose treatment in
addition to fluid replacement for children with cholera is to manage such
patients in resource limited set-ups like during epidemic situation or
man-made disasters, such as observed in Goma in 1994 and Zimbabwe in
2008-9(6,7). Since one of the manifestation of cholera patients is
vomiting, it is important to know how many patients vomited within first
10 minutes who were re-administered second dose, and the use of
unscheduled intravenous fluids between the groups. These are the points to
be considered in planning a policy on the strategy for a single-dose
therapy. Unfortunately we have no clue on these issues from this study.
It is not clear how often the intake and output were
measured. The other major concern is with the definition of clinical
relapse. The earliest point when the patients can be discharged is if
watery stool resolves at 72 h (3 day) and we know the mean duration of
diarrhea among the azithromycin treated group was 54 h (>2 days), whereas
it is stated for defining clinical relapse there has to be a minimum of 24
h without watery stool. I doubt if the patients were kept that long in the
hospital (24h without diarrhea), thus resulting in no clinical relapse in
either treatment group. Ideally, if all patients were kept in the hospital
for 5 days, they could have defined the clinical and bacteriologic relapse
more confidently as observed in earlier studies.
In the discussion section, the authors have argued that
by conducting their study at a tertiary care hospital they provided a more
realistic picture of diarrheal disease burden compared to trial at
diarrheal disease hospital. This argument is surprising since disease
burden study in a tertiary care hospital does not reflect the general
population and moreover this was not the objective of the study.
Conducting the study at a diarrheal disease facility, on the other hand,
has the advantage that the trial can be completed faster producing equally
valid results.
The major strength of the study was the gender balance
although I wonder how they could ensure that urine and stool were not
misinterpreted especially when the subjects were only 2-12 years; no
information was available on this.
Finally, as a reviewer, it is good to see the efficacy
of azithromycin as a single dose but this also has a negative implication
in developing countries like India and Bangladesh, where drugs can be
purchased over the counter. When the lay people/pharmacists know that
single dose azithromycin works against cholera it is likely that the use
of this agent will increase exponentially, a market that pharma-ceuticals
will always like to see. Thus it is important for the policy makers,
regulatory bodies and drug control agencies to keep a vigil on the use of
antimicrobial agents. We have to realize that options diminishing are
against multiple drug resistance (MDR) V. cholerae.
Funding: None.
Competing interests: None stated.
References
1. Kaushik JS, Gupta P, Faridi MMA, Das S. Single-dose
azithromycin versus ciprofloxacin for cholera in children: a randomized
controlled trial. Indian Pediatr 2010; 47: 309-315.
2. Saha D, Karim MM, Khan WA, Ahmed S, Salam MA,
Bennish ML. Single-dose azithromycin for the treatment of cholera in
adults. N Engl J Med 2006; 354: 2452-2462.
3. Khan WA, Bennish ML, Seas C, Khan EH, Ronan A, Dhar
U, et al. Randomized controlled comparison of single-dose
ciprofloxacin and doxycycline for cholera by Vibrio cholerae O1 or
O139. Lancet 1996; 348: 296-300.
4. Khan WA, Saha D, Rahman A, Salam MA, Bogaerts J,
Bennish ML. Comparison of single-dose azithromycin and 12 dose, 3-day
erythromycin for childhood cholera: a randomized, double-blind trial.
Lancet 2002; 360: 1722-1727.
5. Saha D, Khan WA, Karim MM, Chowdhury HR, Salam MA,
Bennish ML. Single-dose ciprofloxacin versus 12-dose erythromycin for
childhood cholera: a randomised controlled trial. Lancet 2005; 366:
1085-1093.
6. Siddique A, Salam A, Islam M, Akram K, Majumdar R,
Zaman K. Why treatment centres failed to prevent cholera deaths among
Rwandan refugees in Goma, Zaire. Lancet 1995; 345: 359-361.
7. World Health Organization, Cholera in Zimbabwe:
Epidemiological Bulletin Number 24 Week 21 (17 - 23 May 2009). Available
at http://www.who.int/hac/crises/zwe/en/index.html. Accessed 20 June,
2009.
|
|
|
|